The blood-brain barrier (BBB) restricts the access of therapeutic agents to the brain,
complicating the treatment of neurological diseases, such as Alzheimer's disease (AD) …

Neurodegenerative disorders including Alzheimer's, Parkinson's, and dementia are chronic
and advanced diseases that are associated with loss of neurons and other related …

The blood–brain barrier (BBB) is considered as the most challenging barrier in brain drug
delivery. Indeed, there is a definite link between the BBB integrity defects and central …

Central nervous system integrity is the state of brain functioning across sensory, cognitive,
emotional-social behaviors, and motor domains, allowing a person to realise his full …

In last two decades, the lipid nanocarriers have been extensively investigated for their drug
targeting efficiency towards the critical areas of the human body like CNS, cardiac region …

The central nervous system (CNS) is vulnerable to pathologic processes that lead to the
development of neurodegenerative disorders like Alzheimer's, Parkinson's and Huntington's …

Nanotechnology exerts an increasing impact on the development of more effective tools for
the diagnosis and treatment of human diseases. This applies in particular to central nervous …

Significant efforts have been made in research to discover newer neurotherapeutics,
however, the rate of reported neurological disorders has been increasing at an alarming …

Solid lipid nanoparticles (SLNs) and nanostructured lipid carriers (NLCs) comprise a
category of versatile drug delivery systems that have been used in the biomedical field for> …

Most of the potential therapeutic agents capable to modulate the pathophysiology or treat
the neurological disorders and brain tumors are useless in the current modern and …